Logo image of TARA

PROTARA THERAPEUTIC INC (TARA) Stock Fundamental Analysis

NASDAQ:TARA - Nasdaq - US74365U1079 - Common Stock - Currency: USD

3.2  -0.06 (-1.84%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TARA. TARA was compared to 550 industry peers in the Biotechnology industry. TARA has a great financial health rating, but its profitability evaluates not so good. TARA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TARA has reported negative net income.
In the past year TARA has reported a negative cash flow from operations.
In the past 5 years TARA always reported negative net income.
TARA had a negative operating cash flow in each of the past 5 years.
TARA Yearly Net Income VS EBIT VS OCF VS FCFTARA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

TARA has a better Return On Assets (-26.94%) than 70.73% of its industry peers.
TARA's Return On Equity of -28.65% is fine compared to the rest of the industry. TARA outperforms 78.55% of its industry peers.
Industry RankSector Rank
ROA -26.94%
ROE -28.65%
ROIC N/A
ROA(3y)-44.56%
ROA(5y)-35.55%
ROE(3y)-50.02%
ROE(5y)-39.26%
ROIC(3y)N/A
ROIC(5y)N/A
TARA Yearly ROA, ROE, ROICTARA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TARA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TARA Yearly Profit, Operating, Gross MarginsTARA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for TARA has been increased compared to 1 year ago.
TARA has more shares outstanding than it did 5 years ago.
TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TARA Yearly Shares OutstandingTARA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TARA Yearly Total Debt VS Total AssetsTARA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 5.19 indicates that TARA is not in any danger for bankruptcy at the moment.
The Altman-Z score of TARA (5.19) is better than 76.91% of its industry peers.
There is no outstanding debt for TARA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.19
ROIC/WACCN/A
WACCN/A
TARA Yearly LT Debt VS Equity VS FCFTARA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 18.03 indicates that TARA has no problem at all paying its short term obligations.
With an excellent Current ratio value of 18.03, TARA belongs to the best of the industry, outperforming 92.73% of the companies in the same industry.
A Quick Ratio of 18.03 indicates that TARA has no problem at all paying its short term obligations.
TARA has a better Quick ratio (18.03) than 92.73% of its industry peers.
Industry RankSector Rank
Current Ratio 18.03
Quick Ratio 18.03
TARA Yearly Current Assets VS Current LiabilitesTARA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.90% over the past year.
EPS 1Y (TTM)48.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TARA will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.75%
EPS Next 2Y13.03%
EPS Next 3Y8.38%
EPS Next 5Y18.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TARA Yearly Revenue VS EstimatesTARA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
TARA Yearly EPS VS EstimatesTARA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TARA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TARA Price Earnings VS Forward Price EarningsTARA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TARA Per share dataTARA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.03%
EPS Next 3Y8.38%

More info and screens

0

5. Dividend

5.1 Amount

TARA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTARA THERAPEUTIC INC

NASDAQ:TARA (8/14/2025, 3:20:35 PM)

3.2

-0.06 (-1.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10
Inst Owners74.91%
Inst Owner Change1.02%
Ins Owners2.82%
Ins Owner Change4.66%
Market Cap123.46M
Analysts83.08
Price Target22.61 (606.56%)
Short Float %7.71%
Short Ratio8.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.04%
Min EPS beat(2)14.97%
Max EPS beat(2)37.1%
EPS beat(4)4
Avg EPS beat(4)25.66%
Min EPS beat(4)5.73%
Max EPS beat(4)44.85%
EPS beat(8)6
Avg EPS beat(8)13.01%
EPS beat(12)9
Avg EPS beat(12)3.35%
EPS beat(16)11
Avg EPS beat(16)2.63%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.59%
EPS NY rev (1m)0%
EPS NY rev (3m)19.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)-1.74
Fwd EYN/A
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0
BVpS4.11
TBVpS4.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.94%
ROE -28.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.56%
ROA(5y)-35.55%
ROE(3y)-50.02%
ROE(5y)-39.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.66%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.03
Quick Ratio 18.03
Altman-Z 5.19
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)18.67%
Cap/Depr(5y)287.2%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y40.75%
EPS Next 2Y13.03%
EPS Next 3Y8.38%
EPS Next 5Y18.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.73%
OCF growth 3YN/A
OCF growth 5YN/A